Multicenter, Randomized, Double-Blind, Parallel-Group Extension To Study Ac-058B201 To Investigate The Long-Term Safety, Tolerability, And Efficacy Of 10, 20, And 40 Mg/Day Ponesimod, An Oral S1p1 Receptor Agonist, In Patients With Relapsing-Remitting Multiple Sclerosis.
Posted Date: Mar 26, 2014
- Investigator: Joseph Nicolas
- Specialties: Multiple Sclerosis, Neurology
- Type of Study: Drug
PURPOSE OF THE STUDY The aims of this study are: • To offer subjects an option to continue treatment with ponesimod, or to initiate treatment with ponesimod if they did not receive active treatment during the core study. • To find out more about the long-term safety and tolerability of ponesimod. • To investigate the long-term effectiveness of ponesimod.
The Subjects All Subjects Who Participated In The Core Study And Completed Their Study Treatment In The Core Study Are Eligible To Enter This Extension Study
Relapsing-Remitting, Neurology, Multiple Sclerosis, Actelion, Null
For More Information: